Brief: Coya Therapeutics, Inc. Announces Expansion Of Exclusive Worldwide Licensing Agreement With Arscience Biotherapeutics, Inc. For Development And Commercialization Of Coya 301, Coya’S Low-Dose Interleukin 2 (Il-2) Product Candidate
15/02/2023 13:17
Feb 15 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS, INC. ANNOUNCES EXPANSION OF EXCLUSIVE
WORLDWIDE LICENSING AGREEMENT WITH ARSCIENCE BIOTHERAPEUTICS,
INC. FOR DEVELOPMENT AND COMMERCIALIZATION OF COYA 301, COYA’S
LOW-DOSE INTERLEUKIN 2 (IL-2) PRODUCT CANDIDATE
* COYA THERAPEUTICS - EXPANSION GRANTS EXCLUSIVE RIGHTS TO
DEVELOP, COMMERCIALIZE COYA 301 AS MONOTHERAPY FOR TREATMENT OF
MULTIPLE AUTOIMMUNE DISEASES
* COYA THERAPEUTICS - COYA HAS BEEN GRANTED RIGHTS TO
DEVELOP AND
COMMERCIALIZE COYA 301 AS A MONOTHERAPY FOR TREATMENT OF
MULTIPLE AUTOIMMUNE DISEASES
Source text for Eikon: ID:nBw2KjjTka
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)